If you or a loved one has lung cancer, you may be looking into different treatment options. One new medicine you may hear about is Ensacove (ensartinib). In December 2024, the FDA approved Ensacove as ...

Amtagvi monotherapy achieved a 25.6% objective response rate and 71.8% disease control rate in NSCLC patients without actionable mutations. The median duration of response was not reached after 25.4 ...

Microsoft and Bristol Myers Squibb have signed a new pact aimed at identifying lung cancer cases more quickly. | Microsoft ...

A 25-year study led by the Barcelona Institute for Global Health finds that PM2.5 increases the risk of all lung cancer subtypes, while several gaseous pollutants are associated with non-small-cell ...

Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...

Please provide your email address to receive an email when new articles are posted on . Guidelines for the management of early-stage non-small cell lung cancer were last published in 2013. The new ...

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...

Despite a significant 48.8% objective response rate and breakthrough therapy status, this regulatory shift reverses years of ...